top of page

Supported by Mainland China Government & Industry

ID (Funding Body)


Title (Start-End, Project Fund)

Prof. Aiping Lyu

NSFC 81673773

The role and molecular mechanism of obesity with Chinese medicine pattern of phlegm-dampness in the pathogenesis of hypertension (2017.1-2020.12, RMB590,000) 

Further research on Jin Gu Lian Capsule and Ai Di Injection for new drug R&D(2015-2018, HK$ 3,200,000)

Efficacy evaluation and mechanism exploration of Pien Tze Huang on multiple sclerosis (2015.7.30-2018.07.30, HK$2,500,000)

New drug R&D for therapeutic RNAi targeting CKIP-1 to reverse bone erosion in Rheumatology Arthritis (2015-2017, RMB3,000,000)

Does aberrantly overexpressed casein kinase-2 interacting protein-1 contribute to failure of osteoblast-mediated repair for bone erosion in rheumatoid arthritis? (2013-2015, HK$3,000,000) 

Research and development of triptolide-aptamer drug (2013.1-2015.12, RMB1,500,000) 

Prof. Ge Zhang

The molecular mechanism of aged-related decrease of osteogenesis in osteoporosis: the effect of miR-214 derived from osteoclasts on osteoblastic activity (2015.11.1-2017.10.31, RMB300,000)

An innovative immuno-chemotherapy for triple-negative breast cancer: PD-L1 aptamer-paclitaxel conjugate (2016.7.1-2019.6.30, RMB3,000,000)

Anti-PD-L1 aptamer in combination of paclitaxel for treating triple-negative breast cancer (2016.05.03-2020.05.02, HK$3000,000)

Aptamer-modified Paclitaxel for Tumor Therapy (2014.9.4-2019.8.3, HK$2,700,000)

Skeletal role of CK2-interating Protein-1 in Regulating Osteoblastic Bone Formation: Molecular Mechanism and Reversing Osteoporosis (2013.1.1-2016.12.31, HK$753,925) 

Study on molecular mechanism of bone formation reduction in aged women: Functional role of CKIP-1 (2013.1.1-2016.12.31, RMB700,000) 

Establishing the bridge for translating cell-specific RNA interference to bone anabolic therapy: An aptamer-functionalized osteoblast-targeting delivery system for osteogenic siRNAs (2013.8.1-2015.8.30, RMB300,000)

Private Fund from 
Gui Zhou Yi Bai

Private Fund from 
Pian Zai Huang

Private Fund from 
Tai De

(Sub-project of National Science and Technology Major Projects for "Major New Drugs Innovation and Development")

Contract Study from Kunshan RNAi Institute

(Science and Technology Innovation Commission of Shenzhen Municipality)

 (Science and Technology Innovation Commission of Shenzhen Municipality)

Private Fund from 
Huabao Ltd.

Private Fund from
from Qinfeng, QFPG/14-15/01-SCMD

(Science and Technology Innovation Commission of Shenzhen Municipality)


NSFC 81272045

bottom of page